Marcom, P Kelly <br/><br/>
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.  [electronic resource] 

 -  Breast cancer research and treatment  Mar 2007 
 - 43-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0167-6806 
<br/><br/><label>Standard No.: </label>10.1007/s10549-006-9307-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--chemistry<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization, Fluorescence<br/>Letrozole<br/>Middle Aged<br/>Nitriles--administration & dosage<br/>Receptor, ErbB-2--analysis<br/>Receptors, Estrogen--analysis<br/>Trastuzumab<br/>Triazoles--administration & dosage